ANL (Adlai Nortye) Accounts Payable: $12.64 Mil (As of Dec. 2025)


What is Adlai Nortye Accounts Payable?

Adlai Nortye ANL -8.78% Accounts Payable is $12.64 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Adlai Nortye's Accounts Payable for the quarter that ended in Dec. 2025 was $12.64 Mil.

Adlai Nortye's quarterly Accounts Payable declined from Dec. 2024 ($10.15 Mil) to Jun. 2025 ($9.68 Mil) but then increased from Jun. 2025 ($9.68 Mil) to Dec. 2025 ($12.64 Mil).

Adlai Nortye's annual Accounts Payable declined from Dec. 2023 ($14.35 Mil) to Dec. 2024 ($10.15 Mil) but then increased from Dec. 2024 ($10.15 Mil) to Dec. 2025 ($12.64 Mil).

Adlai Nortye Accounts Payable Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Accounts Payable Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
2.98 13.10 14.35 10.15 12.64

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only 14.35 11.00 10.15 9.68 12.64

Adlai Nortye Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $12.64 Mil mean?
Adlai Nortye (ANL) has a Accounts Payable of $12.64 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Accounts Payable too high?
Adlai Nortye's current Accounts Payable is $12.64 Mil.
How does Adlai Nortye's Accounts Payable compare to OMER and PRME?
Adlai Nortye's Accounts Payable of $12.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Accounts Payable is $12.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Accounts Payable of $12.64 Mil. The current Accounts Payable is $12.64 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Accounts Payable is $12.64 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.